BioAegis Therapeutics (privately held) announced that it has completed its initial funding of more than $3 million. The company will now seek to open up a US IND and initiate a phase 2b/3 pivotal biomarker-driven test to show that repletion of human plasma gelsolin (pGSN) can prevent the spread of inflammation leading to multiple organ dysfunction syndrome (MODS) in the ICU. BioAegis Therapeutics plans to advance this biologic in the relevant Orphan Indications and to launch an effort to commercialize a plasma gelsolin biomarker diagnostic.
With eleven animal efficacy models and two previous human studies, plasma gelsolin replenishment has shown strong scientific rationale for human efficacy testing at this time. Evidence strongly suggests that Plasma Gelsolin Deficiency (PGD) may have adverse effects on a variety of diseases in both chronic and acute conditions.
As the fourth most prevalent plasma protein and one of the major toxic actin scavengers, pGSN is also known to bind with high affinity to multiple inflammatory mediators and to act as a systemic backstop to maintain local inflammation. In addition, recent breakthrough findings in studies conducted at the Harvard School of Public Health have also shown that, unlike previously known inflammation modulators, pGSN is part of the body’s innate immune system and works to boost the body’s response to pathogens.
Dr. Dr. Thomas Stossel, founding scientist at BioAegis and discoverer of gelsolin, said, “I am very pleased to move forward towards our goal of bringing plasma gelsolin to the clinic, where it has an enormous life-saving potential and a dramatic reduction in health care expenditures. “That’s right.
Dr. Dr. Stossel is Director of Translational Medicine at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School at the American Cancer Society. BioAegis Therapeutics was founded by a group of highly experienced pharmaceutical, diagnostic and financial managers. Its mission is to harness the body’s innate immune system to address serious inflammatory disease outcomes.
Please note that this piece of work originally appeared in English at https://www.vcnewsdaily.com/BioAegis%20Therapeutics/venture-funding.php. As Investocracy aims to bring global startup news and updates in both English and Japanese to you, it’s important that we attribute original source to you. If you have any questions/concerns please write to us at contact@investocracy.co
